Medimmune stops arthritis and psoriasis trials

By Staff Writers
Tuesday, 31 August, 2004

Maryland-based MedImmune has halted the clinical trials of its Vitaxin drug for rheumatoid arthritis and psoriasis, blaming a lack of benefits seen with the experimental treatment.

The drug maker said no safety issues came up during the trial. It will continue to study the compound to treat cancer.

Your stool can reveal your risk of cardiovascular disease

Certain faecal proteins have been linked to deadly cardiovascular conditions. A connection...

Targeting the stress system reduces Parkinson's tremors

The commonly used Parkinson's drug levodopa usually helps with tremors, but it tends to be...

DDX53 gene linked to autism spectrum disorder

While DDX53, located on the X chromosome, is known to play a role in brain development...

Content from other channels on our network

High cost of fall-related injuries in aged care

Vic boosts women's health research

Reframing the diagnosis and treatment of obesity

Endometriosis poses substantial burden on Aust health system

Vaxxas expands work with US Govt agency BARDA for COVID-19 mRNA vaccine

CEFC invests $100 million in affordable, greener housing

Vertical axis wind turbine design set to reduce operating costs

Australian Open set to reduce plastic waste by 400 kg

Storing CO2 in construction materials

B-cycle launches holiday battery safety campaign

The 2025 Global Taste Charts reveal flavour innovations

Top tips for avoiding food contamination

Peanut drying process optimised using moisture monitoring system

A breakthrough in level measurement technology

OFI Weigh and Inspection Solutions acquires HBM Packaging